Pulmonx Corp (LUNG)

As of 31 August 2026, short interest in LUNG is 976,237 shares, down 83,929 shares over the last month. Over the last 48 readings it ranged from 815,603 shares (29 November 2024) to 3,560,455 shares (30 April 2026). The latest reading sits at the bottom of that range. At the reported average volume of 378K shares a day that is 2.6 days to cover.

<iframe src="https://xoomar.com/embed/stocks/lung" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 17 September 2026, the short share of LUNG volume is 57.9%, up 27.4 points over the last five sessions. Over the last 52 readings it ranged from 18.2% (15 September 2026) to 62.0% (9 September 2026). The latest reading sits at the top of that range. The latest reading is 19.3 points above the 30-session average of 38.6%, on 119K shares reported.

As of 25 August 2026, the fails-to-deliver balance in LUNG is 1,382 shares, down 19,632 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (23 October 2025) to 53,992 shares (11 March 2026). The latest reading sits at the bottom of that range.

Insiders at LUNG reported 14 open-market sells worth $177K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Radhakrishnan Srikanth (Chief Science & Techn. Officer) on 2026-09-01.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

4 Form 144 notices on file for LUNG worth $235K at the prices reported; 0 in the last 90 days worth $0. Latest: STEVEN WILLIAMSON filed on 2026-01-22 to sell 48,892 shares ($95K) from 2026-01-22.

13 holders above 5% have filed on LUNG, all on Schedule 13G (passive). The largest reported stake is PRIMECAP MANAGEMENT CO/CA/ at 12.2% of the class (4,956,691 shares), filed 2025-11-13 for an event on 2025-09-30.

6 of the 30 tracked managers held LUNG at their latest 13F, $2.9M in total at quarter-end prices. AQR Capital Management is the largest at $968K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) Pulmonx Corp reported revenue of $22.8M, down 4.6% from the same quarter a year earlier, and net loss of $10.1M (-0.24 diluted EPS). In FY 2025 it generated -$32.4M of operating cash flow. As of 2026-06-30, cash was $55.8M against $37.5M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.